Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10220042 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(4 years from now) | |
US9119791 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(4 years from now) | |
US7910131 | SUPERNUS PHARMS | Method of treating seizures using modified release formulations of oxcarbazepine |
Apr, 2027
(4 years from now) | |
US9855278 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(4 years from now) | |
US11166960 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(4 years from now) | |
US8821930 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(4 years from now) | |
US9351975 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(4 years from now) | |
US7722898 | SUPERNUS PHARMS | Modified-release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(4 years from now) | |
US8617600 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(4 years from now) | |
US9370525 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(4 years from now) |
Market Authorisation Date: 19 October, 2012
Treatment: Treatment of partial-onset seizures
Dosage: TABLET, EXTENDED RELEASE;ORAL
17
United States
2
Japan
2
Spain
2
European Union
1
Germany
1
Austria
1
Canada
1
Australia
1
Mexico
1
China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic